Showing 6951-6960 of 7740 results for "".
- Zeltiq Shines Spotlight on CoolAdvantage Petite Applicator at AAD Annual Meetinghttps://practicaldermatology.com/news/zeltiq-shines-spotlight-on-coolmini-applicator-at-aad-annual-meeting/2458259/ZELTIQ® Aesthetics is showcasing the CoolAdvantage Petite™ applicator at the American Academy of Dermatology Annual Meeting (AAD) in Orlando. The CoolAdvantage technology is the only non-invasive fat removal technology cleared by the Food and Drug Administration (F
- New Research Highlights Need for Greater Sun Safety Educationhttps://practicaldermatology.com/news/new-research-highlights-need-for-greater-sun-safety-education/2458261/Taken together, two new studies provide a mixed bag of news on the effectiveness of public health measures and messages aimed at decreasing skin cancer risk and improving sun safety behaviors. One study show
- Galderma and Colorescience Launch Collaborationhttps://practicaldermatology.com/news/galderma-and-colorescience-launch-collaboration/2458265/Galderma will collaborate with Colorescience to expand skincare solutions to individuals who seek innovative daily skincare products that can be used in conjunction with traditional facial injectable aesthetic treatments, the companies have announced. Galderma and Color
- AAD Launches SkinSerious Campaignhttps://practicaldermatology.com/news/aad-launches-skinserious-campaign/2458268/The American Academy of Dermatology is launching a new campaign to raise awareness of the breadth of serious skin diseases as well as the critical role dermatologists play in an era of team-based health care. The SkinSerious campaign will launc
- Obagi Medical Products Collaborates with Suzan Obagi, MD and Nextcell Medical to Introduce New Linehttps://practicaldermatology.com/news/obagi-medical-products-collaborates-with-suzan-obagi-md-and-nextcell-medical-to-introduce-new-line/2458274/Valeant Pharmaceuticals International, Inc.’s wholly owned subsidiary Obagi Medical Products collaborated with Nextcell Medical Company to claim exclusive distribution of Suzan Obagi, MD’s line of skin care products throughout the United States. Established in 2013 with cosmetic
- DermMentors™ 2017 Resident of Distinction Award Honors Five Dermatology Residentshttps://practicaldermatology.com/news/dermmentors-2017-resident-of-distinction-award-honors-five-dermatology-residents/2458273/As part of the dermMentors™ Resident of Distinction Award program, sponsored by Beiersdorf Inc., five dermatology residents attended the 16th Annual Caribbean Dermatology Symposium in Aruba, Netherlands Antilles, from January 17 - 21, 2017
- CareCredit to Acquire CitiHealth Card Portfoliohttps://practicaldermatology.com/news/carecredit/2458277/CareCredit has signed an agreement with Citibank, N.A. to acquire the Citi Health Card portfolio, further expanding its healthcare acceptance network in the United States. The portfolio acquisition includes more than 14,500 providers,
- Save The Dates: ASLMS to Host 37th Annual Conference In Early April 2017https://practicaldermatology.com/news/save-the-dates-aslms-to-host-37th-annual-conference-in-early-april-2017/2458279/American Society for Laser Medicine and Surgery (ASLMS) 2017 will take place April 5 – 9, 2017 in San Diego, Calif. New for 2017 is a special CME Session, Moving from the Lab to the Clinic, which will focus on the translation of technolog
- Clarisonic Introduces the Smart Profile Uplifthttps://practicaldermatology.com/news/clarisonic-introduces-the-smart-profile-uplift/2458281/Clarisonic is rolling out a new at-home device, the Smart Profile Uplift. This 2-in-1 skincare device combines Clarisonic's cleansing with a new firming massage head. In clinical testing performed by the
- FDA Approves Valeant's SILIQ For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-valeants-siliq-for-moderate-to-severe-plaque-psoriasis/2458283/The FDA has approved the Biologics License Application (BLA) for Valeant Pharmaceutical's SILIQ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis. SILIQ is indicated for the treatment of mo